Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Back to dashboard
Company Information
About this company
Key people
Roger D. Kornberg
Independent Chairman of the Board
Sam Lee
President, Chief Scientific Officer
James Sapirstein
Chief Executive Officer
James J. Martin
Chief Financial Officer
Carol L. Brosgart
Director
Phillip Frost
Independent Director
Fred Hassan
Independent Director
Anthony J. Japour
Independent Director
Click to see more
Key facts
- Shares in issue19.26m
- EPICCOCP
- ISINUS19188J4094
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$21.38m
- Employees10
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.